Literature DB >> 3459199

A rat gastric mucosal preparation for studying agents which affect the in vitro production of prostanoids.

R Melarange, L C Rashbrook.   

Abstract

A convenient and reproducible method for measuring the production of prostanoids from either the rat gastric mucosa or whole corpus tissue is described. Use of selective radio-immunoassay was employed to measure production of 6-keto- PGF1 alpha, the stable hydrolysis product of PGI2, and PGE2. The mucosal tissue generated approximately 10 times more 6-keto-PGF1 alpha than PGE2. Gastric muscle tissue, however, produced 2-3 times more 6-keto-PGF1 alpha than the mucosa. Exogenous arachidonic acid was found to elevate the amount of both prostanoids although the rate of formation of 6-keto-PGF1 alpha appeared to be less than that of PGE2. A possible explanation for this was that PGE2 production, in part, was non-enzymic. Mepacrine, a phospholipase inhibitor, was found to inhibit both the control amounts of 6-keto-PGF1 alpha and the increased production of this prostanoid due to exogenous phospholipase activity. The generation of prostanoids was also inhibited by indomethacin in a concentration-related manner which suggested that the method is suitable for screening non-steroidal anti-inflammatory agents in vitro or ex vivo. Preliminary results with the above method have been reported elsewhere.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459199     DOI: 10.1016/0262-1746(86)90025-9

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  2 in total

1.  Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin.

Authors:  R Melarange; C Gentry; C O'Connell; P R Blower; C Neil; A S Kelvin; C D Toseland
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

2.  Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.

Authors:  R Melarange; C Gentry; M Durie; C O'Connell; P R Blower
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.